期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 170, 期 1, 页码 85-95出版社
WILEY-BLACKWELL
DOI: 10.1111/bjh.13399
关键词
follicular lymphoma; elderly patients; elderly lymphoma; rituximab; chemotherapy
类别
资金
- Genentech (South San Francisco, CA, USA)/F. Hoffmann-La Roche (Basel, Switzerland)
- Genentech
Data from the National LymphoCare Study (a prospective, multicentre registry that enrolled follicular lymphoma (FL) patients from 2004 to 2007) were used to determine disease characteristics, treatment patterns, outcomes and prognosis for elderly FL (eFL) patients. Of 2650 FL patients, 209 (8%) were aged >80years; these eFL patients more commonly had grade 3 disease, less frequently received chemoimmunotherapy and anthracyclines, and had lower response rates when compared to younger patients. With a median follow-up of 6.9years, 5-year overall survival (OS) for eFL patients was 59%; 38% of deaths were lymphoma-related. No treatment produced superior OS among eFL patients. In multivariate Cox models, anaemia, B-symptoms and male sex predicted worse OS (P<001); a prognostic index of these factors (0, 1 or 2 present) predicted OS [hazard ratio (95% CI): 2 vs. 0, 472 (238-933); 1 vs. 0, 263 (139-498)], with a higher concordance index (063) versus the Follicular Lymphoma International Prognostic Index (055). The index was validated in an independent cohort. In the largest prospective US-based eFL cohort, no optimal therapy was identified and nearly 40% of deaths were lymphoma-related, representing baseline outcomes in the modern era.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据